The promise of precision oncology
brought to life for patients
KURA REPORTS POSITIVE PRELIMINARY ZIFTOMENIB COMBINATION DATA IN ACUTE MYELOID LEUKEMIA
Preliminary clinical data from the first 20 patients in KOMET-007, a Phase 1 dose-escalation trial of the Company’s potent and selective menin inhibitor, ziftomenib, in combination with standards of care, including cytarabine/daunorubicin (7+3) and venetoclax/azacitidine (ven/aza), in patients with NPM1-mutant and KMT2A-rearranged AML.
What pharma can teach biotech about the life cycle management of a drug
/in CurrentsNavigating dose optimization requirements as a small biotech
/in CurrentsLiquid Biopsies Guide the Development of Cancer Drugs
/in CurrentsLiquid Biopsies Guide the Development of Cancer Drugs
Fierce Biotech: FDA’s renewed focus on oncology dosing spooks investors, but companies say they’re ready
/in CurrentsESMO: Tipifarnib demonstrates encouraging efficacy in patients with recurrent and/or metastatic hnscc with hras mutations
/in CurrentsJournal of Clinical Oncology: Is This the Dawn of Precision Oncology in Head and Neck Cancer?
/in Currents